Catheter Ablation Versus Antiarrythmic Drugs for Atrial Fibrillation in China

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1800 participants.

Also called NCT01341353

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,800 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01341353
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01341353. Non-randomized; no masking; primary purpose treatment. Start 2011-04 (registry gives no type); primary completion 2014-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Catheter Ablation Versus Antiarrythmic Drugs for Atrial Fibrillation in China
Intervention (Procedure)
catheter ablation
Intervention (Drug)
Digaoxin,amiodarone,β receptor antagonist, Calcium Antagonists
Lead sponsor
Wuhan University (class: other)
Collaborator
Capital Medical University (class: other)
Collaborator
Peking Union Medical College (class: other)
Collaborator
Guangdong Provincial People's Hospital (class: other)
Collaborator
Nanjing Medical University (class: other)
Collaborator
West China Hospital (class: other)
Collaborator
Dalian Medical University (class: other)
Collaborator
Shanghai Chest Hospital (class: other)

Record details

Record id
cardio:ct-nct01341353
Content hash
52465f84d7c87d159aa349f261e8526a72d56b7477bbd025bd87519fda91a8e5